Gland Pharma gets EIR from USFDA for Pashamylaram facility

18 Jan 2025 Evaluate

Gland Pharma has received Establishment Inspection Report (EIR) from the USFDA for its Pashamylaram facility at Hyderabad. USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 25, 2024 and August 02, 2024. The said inspection was concluded with three 483 Observations. 

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1681.95 -39.70 (-2.31%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×